Real-World Efficacy, Safety, and Drug Retention of Anakinra and Canakinumab in Pediatric Colchicine-Resistant Familial Mediterranean Fever: Insights from a Single-Center Cohort

Key Points

• This research aims to evaluate the efficacy and safety of anakinra and canakinumab in pediatric patients with colchicine-resistant Familial Mediterranean Fever (cr-FMF).
• Single-center cohort study of pediatric patients with colchicine-resistant FMF
• Assessment of treatment efficacy on disease activity and inflammation
• Monitoring for side effects and complications during treatment
• Anakinra effectively reduced disease activity and provided rapid symptom relief
• Canakinumab controlled disease with fewer local side effects
• Injection site reactions were frequent with anakinra, while monitoring for rare complications was needed with canakinumab